Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Alumis (ALMS) gained 100%+ after positive Phase 3 psoriasis trial results and raised cash position, supported by strong technical momentum, positioning as a hot idea with near-term FDA submission catalyst.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Higher lows ⢠Support holding ⢠Failed breakout Support Level: $26.5-$27.3 Resistance Level: $30.0-$30.3 ALMS remains in an upward trend over the last month, holding above $26.5-$27.3 support, but repeated failures near $30.0-$30.3 show weakening momentum and a need for a clean reclaim of $30.
Sentiment & News
Key News Insights: ⢠Price breakout ⢠Light volume ⢠No catalyst Alumis Inc. rose 5.7% to $28.78 on below-average volume, signaling a sharp but lightly supported move with no additional catalyst confirmed.
AI Summary
ALMS has shifted from a speculative clinical-stage bet to a more credible late-stage asset story, with the Phase 3 psoriasis win, NDA planned for 2H26, and a cash runway into 4Q27 improving the downside floor, but the stock now hinges on execution of the SLE readout and regulatory timeline because much of the upside is already priced in.
Description
Alumis Inc. is a clinical-stage biopharmaceutical company developing allosteric TYK2 inhibitors to treat autoimmune conditions. Its lead program, ESK-001, is in clinical development for dermatologic, systemic and ocular autoimmune disorders, while A-005 is a CNS-penetrant candidate intended for neuroinflammatory and neurodegenerative indications. The company was incorporated in 2021, renamed from Esker Therapeutics in January 2022, and is based in South San Francisco, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jan 29 | Feb 5 | ALMS | Alumis Inc. Common Stock | Alumis (ALMS) gained 100%+ after positive Phase 3 psoriasis trial results and raised cash position, supported by strong technical momentum, positioning as a hot idea with near-term FDA submission catalyst. | Closed | -1.9% |
| Jan 7 | Jan 14 | ALMS | Alumis Inc. Common Stock | Selected due to recent Phase 3 clinical trial success on 2026-01-07 driving strong near-term momentum and technical breakout; event-driven upside expected from FDA submission and regulatory catalysts. | Closed | +35.8% |